Hansa Biopharma AB (FRA:24H) Short Interest


FRA:24H Hansa Biopharma AB FRA:24H
59 GF Score
Price €2.90
GF Value €2.08
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:24H vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Short Interest falls into.


FRA:24H
59GF Score
Hansa Biopharma AB FRA:24H
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (FRA:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €2.90 is trading 39.5% above its estimated GF Value™ of €2.08. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for FRA:24H:

  • Short Interest:
  • GF Value™: €2.08 vs. price of €2.90 (39.5% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
59GF Score

Get the complete analysis for FRA:24H

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€2.08
GF Value